Is MDXH or RNA more profitable?

Avidity Biosciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -24.25% Avidity Biosciences N/A N/A N/A

Does the media favor MDXH or RNA?

In the previous week, MDxHealth had 7 more articles in the media than Avidity Biosciences. MarketBeat recorded 8 mentions for MDxHealth and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.13 beat MDxHealth's score of -0.26 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MDXH or NGEN more profitable?

NervGen Pharma has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -24.25% NervGen Pharma N/A -1,259.82% -199.79%

Does the media prefer MDXH or NGEN?

In the previous week, MDxHealth had 5 more articles in the media than NervGen Pharma. MarketBeat recorded 8 mentions for MDxHealth and 3 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.16 beat MDxHealth's score of -0.26 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDXH or ABOS?

In the previous week, MDxHealth had 6 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 8 mentions for MDxHealth and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.05 beat MDxHealth's score of -0.26 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDXH or VYGR?

In the previous week, MDxHealth had 7 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for MDxHealth and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat MDxHealth's score of -0.26 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, KRRO or MDXH?

MDxHealth has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 19.57 -$117.26M -$10.00 N/A MDxHealth $107.88M 0.09 -$33.52M -$0.72 N/A

Is KRRO or MDXH more profitable?

Korro Bio has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio N/A -114.26% -68.57% MDxHealth -33.46% N/A -24.25%

Does the media favor KRRO or MDXH?

In the previous week, MDxHealth had 4 more articles in the media than Korro Bio. MarketBeat recorded 8 mentions for MDxHealth and 4 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.78 beat MDxHealth's score of -0.26 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MDxHealth (MDXH) Competitors

$0.21 -0.40 (-65.77%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.19 -0.01 (-6.10%)

As of 10/16/2026 07:59 PM Eastern

Compare

MDXH vs. RNA, NGEN, ABOS, VYGR, and KRRO

Should you buy MDxHealth stock or one of its competitors? MDxHealth's main competitors and comparable companies include Avidity Biosciences (RNA), NervGen Pharma (NGEN), Acumen Pharmaceuticals (ABOS), Voyager Therapeutics (VYGR), and Korro Bio (KRRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MDxHealth compare to Avidity Biosciences?

MDxHealth (NASDAQ:MDXH) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Avidity Biosciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Avidity Biosciences	N/A	N/A	N/A

Avidity Biosciences has lower revenue, but higher earnings than MDxHealth. Avidity Biosciences is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.09	-$33.52M	-$0.72	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

In the previous week, MDxHealth had 7 more articles in the media than Avidity Biosciences. MarketBeat recorded 8 mentions for MDxHealth and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.13 beat MDxHealth's score of -0.26 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MDxHealth currently has a consensus target price of $1.33, indicating a potential upside of 545.37%. Avidity Biosciences has a consensus target price of $63.75, indicating a potential upside of 731.16%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Avidity Biosciences beats MDxHealth on 7 of the 11 factors compared between the two stocks.

How does MDxHealth compare to NervGen Pharma?

MDxHealth (NASDAQ:MDXH) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, MDxHealth had 5 more articles in the media than NervGen Pharma. MarketBeat recorded 8 mentions for MDxHealth and 3 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.16 beat MDxHealth's score of -0.26 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NervGen Pharma has lower revenue, but higher earnings than MDxHealth. NervGen Pharma is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.09	-$33.52M	-$0.72	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

MDxHealth presently has a consensus price target of $1.33, suggesting a potential upside of 545.37%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 780.50%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NervGen Pharma is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

NervGen Pharma has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
NervGen Pharma	N/A	-1,259.82%	-199.79%

Summary

NervGen Pharma beats MDxHealth on 7 of the 11 factors compared between the two stocks.

How does MDxHealth compare to Acumen Pharmaceuticals?

MDxHealth (NASDAQ:MDXH) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

MDxHealth has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

MDxHealth has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.09	-$33.52M	-$0.72	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

MDxHealth presently has a consensus price target of $1.33, indicating a potential upside of 545.37%. Acumen Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 314.20%. Given MDxHealth's higher probable upside, research analysts plainly believe MDxHealth is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, MDxHealth had 6 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 8 mentions for MDxHealth and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.05 beat MDxHealth's score of -0.26 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

MDxHealth beats Acumen Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does MDxHealth compare to Voyager Therapeutics?

MDxHealth (NASDAQ:MDXH) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

MDxHealth has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.09	-$33.52M	-$0.72	N/A
Voyager Therapeutics	$40.37M	2.90	-$119.72M	-$1.80	N/A

In the previous week, MDxHealth had 7 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for MDxHealth and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.42 beat MDxHealth's score of -0.26 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MDxHealth currently has a consensus target price of $1.33, indicating a potential upside of 545.37%. Voyager Therapeutics has a consensus target price of $16.50, indicating a potential upside of 768.42%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

MDxHealth has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

MDxHealth has a net margin of -33.46% compared to Voyager Therapeutics' net margin of -312.63%. MDxHealth's return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Voyager Therapeutics	-312.63%	-57.92%	-45.00%

48.0% of Voyager Therapeutics shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MDxHealth beats Voyager Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MDxHealth compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Korro Bio has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-114.26%	-68.57%
MDxHealth	-33.46%	N/A	-24.25%

In the previous week, MDxHealth had 4 more articles in the media than Korro Bio. MarketBeat recorded 8 mentions for MDxHealth and 4 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.78 beat MDxHealth's score of -0.26 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Korro Bio currently has a consensus target price of $16.50, suggesting a potential upside of 94.35%. MDxHealth has a consensus target price of $1.33, suggesting a potential upside of 545.37%. Given MDxHealth's higher possible upside, analysts clearly believe MDxHealth is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
MDxHealth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Korro Bio has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

MDxHealth has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	19.57	-$117.26M	-$10.00	N/A
MDxHealth	$107.88M	0.09	-$33.52M	-$0.72	N/A

13.2% of Korro Bio shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Korro Bio beats MDxHealth on 9 of the 16 factors compared between the two stocks.

Get MDxHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXH vs. The Competition

Export

Metric	MDxHealth	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$29.88M	$3.97B	$7.44B	$12.94B
Dividend Yield	N/A	3.64%	2.50%	27.63%
P/E Ratio	-0.29	9.17	197.60	19.02
Price / Sales	0.09	1,172.40	568.90	76.65
Price / Cash	N/A	122.10	76.54	51.88
Price / Book	-0.86	15.94	10.29	5.85
Net Income	-$33.52M	-$22.69M	$3.50B	$380.67M
7 Day Performance	-64.97%	-8.66%	-5.38%	-5.00%
1 Month Performance	-69.24%	-15.39%	-9.56%	-7.94%
1 Year Performance	-94.85%	1.51%	0.84%	-5.63%

MDxHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXH MDxHealth	2.662 of 5 stars	$0.21 -65.8%	$1.33 +545.4%	-94.9%	$29.88M	$107.88M	N/A	364	News Coverage Analyst Downgrade Gap Down High Trading Volume
RNA Avidity Biosciences	2.065 of 5 stars	$7.80 +0.6%	$63.75 +717.3%	-84.3%	$133.46M	N/A	N/A	190
NGEN NervGen Pharma	1.7085 of 5 stars	$1.64 +0.6%	$14.00 +754.2%	N/A	$132.15M	N/A	N/A	8	Positive News
ABOS Acumen Pharmaceuticals	2.6137 of 5 stars	$1.84 +0.8%	$7.00 +281.5%	-20.7%	$131.48M	N/A	N/A	61	Positive News Gap Up
VYGR Voyager Therapeutics	2.8406 of 5 stars	$2.13 -1.2%	$16.50 +676.5%	-64.4%	$130.94M	$40.37M	N/A	141	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXH) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MDxHealth (MDXH) Competitors

MDXH vs. RNA, NGEN, ABOS, VYGR, and KRRO

How does MDxHealth compare to Avidity Biosciences?

Summary

How does MDxHealth compare to NervGen Pharma?

Summary

How does MDxHealth compare to Acumen Pharmaceuticals?

Summary

How does MDxHealth compare to Voyager Therapeutics?

Summary

How does MDxHealth compare to Korro Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MDxHealth (MDXH) Competitors

MDXH vs. RNA, NGEN, ABOS, VYGR, and KRRO

How does MDxHealth compare to Avidity Biosciences?

Is MDXH or RNA more profitable?

Which has higher valuation and earnings, MDXH or RNA?

Does the media favor MDXH or RNA?

Do analysts recommend MDXH or RNA?

Summary

How does MDxHealth compare to NervGen Pharma?

Does the media prefer MDXH or NGEN?

Which has better valuation & earnings, MDXH or NGEN?

Do analysts recommend MDXH or NGEN?

Is MDXH or NGEN more profitable?

Summary

How does MDxHealth compare to Acumen Pharmaceuticals?

Which has more risk and volatility, MDXH or ABOS?

Which has stronger earnings & valuation, MDXH or ABOS?

Is MDXH or ABOS more profitable?

Do analysts rate MDXH or ABOS?

Does the media favor MDXH or ABOS?

Do insiders & institutionals believe in MDXH or ABOS?

Summary

How does MDxHealth compare to Voyager Therapeutics?

Which has better valuation & earnings, MDXH or VYGR?

Does the media prefer MDXH or VYGR?

Do analysts prefer MDXH or VYGR?

Which has more risk and volatility, MDXH or VYGR?

Is MDXH or VYGR more profitable?

Do insiders and institutionals have more ownership in MDXH or VYGR?

Summary

How does MDxHealth compare to Korro Bio?

Is KRRO or MDXH more profitable?

Does the media favor KRRO or MDXH?

Do analysts prefer KRRO or MDXH?

Which has more volatility and risk, KRRO or MDXH?

Which has stronger valuation & earnings, KRRO or MDXH?

Do insiders and institutionals hold more shares of KRRO or MDXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools